Is ruxolitinib cream the same as ruxolitinib?

Ruxolitinib cream and ruxolitinib are not exactly the same. Although they both involve a similar drug ingredient, Ruxolitinib (Ruxolitinib), they differ in drug form, use and administration.

Ruxolitinib is a small molecule Januskinase (JAK) inhibitor, specifically an inhibitor of JAK1 and JAK2. It was originally developed as an oral medication to treat blood disorders such as myelofibrosis. Ruxolitinib cream is a topical formulation of ruxolitinib, specially designed for localized skin inflammation. This medication in cream form can be applied directly to the affected skin.

Ruxolitinib oral preparation is mainly used to treat myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. In addition, it is also being used exploratoryly to treat other inflammatory diseases, such as atopic dermatitis.

Ruxolitinib cream is mainly used to treat autoimmune inflammatory skin diseases, such as vitiligo, atopic dermatitis (AD), etc. Its phase 3 clinical trial showed that when treating atopic dermatitis, a higher proportion of patients who used ruxolitinib cream achieved treatment success than those who received no cream.

Ruxolitinib is an oral drug that needs to be absorbed through the digestive system and acts throughout the body. Therefore, it may cause some systemic side effects. Ruxolitinib cream is a topical drug that is applied directly to the affected area, which reduces systemic side effects and improves the safety and local effect of the drug.

Ruxolitinib is the first drug approved by the FDA to treat myelofibrosis, and was later approved by the European Union, Japan and other countries and regions. Ruxolitinib cream is a topical preparation based on the patented formula of ruxolitinib. It was approved by the US FDA in 2022 for the topical treatment of non-segmental vitiligo in patients aged 12 years and above, as well as other autoimmune inflammatory skin diseases.